

contractual agreement under which the manufacturer agrees to bear the cost of such litigation or to conduct such litigation.

(Pub. L. 105-230, §6, Aug. 13, 1998, 112 Stat. 1526.)

§ 1606. Subsequent impleader of dismissed biomaterials supplier

(a) Impleading of dismissed defendant

A court, upon motion by a manufacturer or a claimant within 90 days after entry of a final judgment in an action by the claimant against a manufacturer, and notwithstanding any otherwise applicable statute of limitations, may implead a biomaterials supplier who has been dismissed from the action pursuant to this chapter if—

(1) the manufacturer has made an assertion, either in a motion or other pleading filed with the court or in an opening or closing statement at trial, or as part of a claim for contribution or indemnification, and the court finds based on the court's independent review of the evidence contained in the record of the action, that under applicable law—

(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and

(B) the manufacturer's liability for damages should be reduced in whole or in part because of such negligence or intentionally tortious conduct; or

(2) the claimant has moved to implead the supplier and the court finds, based on the court's independent review of the evidence contained in the record of the action, that under applicable law—

(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and

(B) the claimant is unlikely to be able to recover the full amount of its damages from the remaining defendants.

(b) Standard of liability

Notwithstanding any preliminary finding under subsection (a) of this section, a biomaterials supplier who has been impleaded into an action covered by this chapter, as provided for in this section—

(1) may, prior to entry of judgment on the claim against it, supplement the record of the proceeding that was developed prior to the grant of the motion for impleader under subsection (a) of this section; and

(2) may be found liable to a manufacturer or a claimant only to the extent required and permitted by any applicable State or Federal law other than this chapter.

(c) Discovery

Nothing in this section shall give a claimant or any other party the right to obtain discovery from a biomaterials supplier at any time prior to grant of a motion for impleader beyond that allowed under section 1605 of this title.

(Pub. L. 105-230, §7, Aug. 13, 1998, 112 Stat. 1528.)

CHAPTER 22—NATIONAL DRUG CONTROL POLICY

Sec. 1701. 1702.	Definitions. Office of National Drug Control Policy. (a) Establishment of Office. (b) Director and Deputy Directors. (c) Access by Congress. (d) Office of National Drug Control Policy Gift Fund.
1703.	Appointment and duties of Director and Deputy Directors. (a) Appointment. (b) Responsibilities. (c) National Drug Control Program budget. (d) Powers of the Director. (e) Personnel detailed to Office. (f) Fund control notices. (g) Inapplicability to certain programs. (h) Construction.
1704.	Coordination with National Drug Control Program agencies in demand reduction, supply reduction, and State and local affairs. (a) Access to information. (b) Certification of policy changes to Director. (c) General Services Administration. (d) Accounting of funds expended.
1705.	Development, submission, implementation, and assessment of National Drug Control Strategy. (a) Timing, contents, and process for development and submission of National Drug Control Strategy. (b) Annual strategy report. (c) Performance measurement system.
1706.	High Intensity Drug Trafficking Areas Program. (a) Establishment. (b) Designation. (c) Factors for consideration. (d) Use of funds.
1707.	Counter-Drug Technology Assessment Center. (a) Establishment. (b) Director of Technology. (c) Additional responsibilities of the Director of National Drug Control Policy. (d) Assistance and support to Office of National Drug control Policy.
1708.	President's Council on Counter-Narcotics. (a) Establishment. (b) Membership. (c) Functions. (d) Administration.
1709.	Parents Advisory Council on Youth Drug Abuse. (a) In general. (b) Duties of Council. (c) Expenses. (d) Authorization of appropriations.
1710.	Drug interdiction. (a) Definition. (b) Report. (c) Budget process.
1711. 1712.	Authorization of appropriations. Termination of Office of National Drug Control Policy. (a) In general. (b) Exception.
1713.	Authorization of use of environmentally-approved herbicides to eliminate illicit narcotics crops.

§ 1701. Definitions

In this chapter: